These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1856 related articles for article (PubMed ID: 34341184)
1. A combined hypoxia and immune gene signature for predicting survival and risk stratification in triple-negative breast cancer. Yang X; Weng X; Yang Y; Zhang M; Xiu Y; Peng W; Liao X; Xu M; Sun Y; Liu X Aging (Albany NY); 2021 Aug; 13(15):19486-19509. PubMed ID: 34341184 [TBL] [Abstract][Full Text] [Related]
2. Identification and validation of a combined hypoxia and immune index for triple-negative breast cancer. Zheng S; Zou Y; Liang JY; Xiao W; Yang A; Meng T; Lu S; Luo Z; Xie X Mol Oncol; 2020 Nov; 14(11):2814-2833. PubMed ID: 32521117 [TBL] [Abstract][Full Text] [Related]
3. Identification and Validation of a Novel Glycolysis-Related Gene Signature for Predicting the Prognosis and Therapeutic Response in Triple-Negative Breast Cancer. Zheng J; Zhang YF; Han GH; Fan MY; Du MH; Zhang GC; Zhang B; Qiao J; Zhang SX; Cao JM Adv Ther; 2023 Jan; 40(1):310-330. PubMed ID: 36316558 [TBL] [Abstract][Full Text] [Related]
4. Identification of m6A modification patterns and development of m6A-hypoxia prognostic signature to characterize tumor microenvironment in triple-negative breast cancer. Shen X; Zhong J; He J; Han J; Chen N Front Immunol; 2022; 13():978092. PubMed ID: 36105819 [TBL] [Abstract][Full Text] [Related]
5. A novel model associated with tumor microenvironment on predicting prognosis and immunotherapy in triple negative breast cancer. Zhang J; Zhang M; Tian Q; Yang J Clin Exp Med; 2023 Nov; 23(7):3867-3881. PubMed ID: 37219794 [TBL] [Abstract][Full Text] [Related]
6. Comprehensive characterization of stemness-related lncRNAs in triple-negative breast cancer identified a novel prognostic signature related to treatment outcomes, immune landscape analysis and therapeutic guidance: a silico analysis with in vivo experiments. Zhang M; Zhang F; Wang J; Liang Q; Zhou W; Liu J J Transl Med; 2024 May; 22(1):423. PubMed ID: 38704606 [TBL] [Abstract][Full Text] [Related]
7. A novel fatty-acid metabolism-based classification for triple negative breast cancer. Yang X; Tang W; He Y; An H; Wang J Aging (Albany NY); 2023 Feb; 15(4):1177-1198. PubMed ID: 36880837 [TBL] [Abstract][Full Text] [Related]
8. A novel immune checkpoint-related gene signature for predicting overall survival and immune status in triple-negative breast cancer. Liu J; Ling Y; Su N; Li Y; Tian S; Hou B; Luo S; Zhao L; Shi M Transl Cancer Res; 2022 Jan; 11(1):181-192. PubMed ID: 35261895 [TBL] [Abstract][Full Text] [Related]
9. A Novel Inflammatory Response-Related Gene Signature Predicts Immune Status and Prognosis of Breast Cancer. Zhao R; Xie C; Gong Y; Wei S; Yuan M; Gan J; Chen W J Oncol; 2022; 2022():5468858. PubMed ID: 36467500 [TBL] [Abstract][Full Text] [Related]
10. Identification of the prognostic value of ferroptosis-related gene signature in breast cancer patients. Wang D; Wei G; Ma J; Cheng S; Jia L; Song X; Zhang M; Ju M; Wang L; Zhao L; Xin S BMC Cancer; 2021 May; 21(1):645. PubMed ID: 34059009 [TBL] [Abstract][Full Text] [Related]
11. Development of a novel hypoxia-immune-related LncRNA risk signature for predicting the prognosis and immunotherapy response of colorectal cancer. Luan L; Dai Y; Shen T; Yang C; Chen Z; Liu S; Jia J; Li Z; Fang S; Qiu H; Cheng X; Yang Z Front Immunol; 2022; 13():951455. PubMed ID: 36189298 [TBL] [Abstract][Full Text] [Related]
12. Development and validation of a hypoxia-immune-based microenvironment gene signature for risk stratification in gastric cancer. Liu Y; Wu J; Huang W; Weng S; Wang B; Chen Y; Wang H J Transl Med; 2020 May; 18(1):201. PubMed ID: 32410620 [TBL] [Abstract][Full Text] [Related]
13. Development and verification of a novel immunogenic cell death-related signature for predicting the prognosis and immune infiltration in triple-negative breast cancer. Li J; Li Z; Yang W; Pan J; You H; Yang L; Zhang X Cancer Rep (Hoboken); 2024 Mar; 7(3):e2007. PubMed ID: 38425247 [TBL] [Abstract][Full Text] [Related]
14. Combined mRNAs and clinical factors model on predicting prognosis in patients with triple-negative breast cancer. Hu Y; Zou D PLoS One; 2021; 16(12):e0260811. PubMed ID: 34965257 [TBL] [Abstract][Full Text] [Related]
15. Identification of Novel Anoikis-Related Gene Signatures to Predict the Prognosis, Immune Microenvironment, and Drug Sensitivity of Breast Cancer Patients. Liu J; Wu H; Wang Q; Jin S; Hou S; Shen Z; Zhao L; Xu S; Pang D Cancer Control; 2024; 31():10732748241288118. PubMed ID: 39340434 [TBL] [Abstract][Full Text] [Related]
16. Development and Validation of an Inflammatory Response-Related Gene Signature for Predicting the Prognosis of Pancreatic Adenocarcinoma. Deng ZL; Zhou DZ; Cao SJ; Li Q; Zhang JF; Xie H Inflammation; 2022 Aug; 45(4):1732-1751. PubMed ID: 35322324 [TBL] [Abstract][Full Text] [Related]
17. An iron metabolism and immune related gene signature for the prediction of clinical outcome and molecular characteristics of triple-negative breast cancer. Li XF; Fu WF; Zhang J; Song CG BMC Cancer; 2022 Jun; 22(1):619. PubMed ID: 35668369 [TBL] [Abstract][Full Text] [Related]
18. Novel molecular insights into pyroptosis in triple-negative breast cancer prognosis and immunotherapy. Yu B; Luo J; Yang Y; Zhen K; Shen B J Gene Med; 2024 Jan; 26(1):e3645. PubMed ID: 38041540 [TBL] [Abstract][Full Text] [Related]
19. Identification of prognostic immune-related gene signature associated with tumor microenvironment of colorectal cancer. Wang Y; Li W; Jin X; Jiang X; Guo S; Xu F; Su X; Wang G; Zhao Z; Gu X BMC Cancer; 2021 Aug; 21(1):905. PubMed ID: 34364366 [TBL] [Abstract][Full Text] [Related]
20. Nomogram Personalizes and Visualizes the Overall Survival of Patients with Triple-Negative Breast Cancer Based on the Immune Genome. Wang P; Fu Y; Chen Y; Li Q; Hong Y; Liu T; Ding Z Biomed Res Int; 2020; 2020():4029062. PubMed ID: 33299869 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]